ONKOTRONE

This brand name is authorized in Australia, Estonia, Lithuania, Malta, New Zealand, Romania, UK.

Active ingredients

The drug ONKOTRONE contains one active pharmaceutical ingredient (API):

1	Mitoxantrone UNII BZ114NVM5P - MITOXANTRONE
	Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA.
	Read more about Mitoxantrone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ONKOTRONE Concentrate for solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01DB07	Mitoxantrone	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4514N, 7252Q
EE	Ravimiamet	1011621, 1069950, 1069961, 1069972
GB	Medicines & Healthcare Products Regulatory Agency	44661, 44676
LT	Valstybinė vaistų kontrolės tarnyba	1007455, 1067038
MT	Medicines Authority	AA1277/04401
NZ	Medicines and Medical Devices Safety Authority	9035
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W42735002, W42735003, W42735004, W42735005